OSANG HEALTHCARE was established in 1996
with the mission of "contributing to global health
through early and affordable disease diagnosis."
OSANG HEALTHCARE
was established in 1996
with the mission of "contributing
to global health through early
and affordable disease diagnosis."
Over the past 30 years, OSANG HEALTHCARE has built a robust portfolio
across various diagnostic fields, including biochemistry, immunology, and
molecular diagnostics, and has exported products to over 100 countries
worldwide. With Advanced technology and a solid global distribution
network, we have achieved continuous growth and are poised to become a
major global player through ongoing innovation and strategic investments.
Over the past 30 years, OSANG HEALTHCARE has built
a robust portfolio across various diagnostic fields,
including biochemistry, immunology,
and molecular diagnostics, and has exported products
to over 100 countries worldwide.
With Advanced technology
and a solid global distribution network,
we have achieved continuous growth
and are poised to become a
major global player through ongoing innovation
and strategic investments.
History
We have grown into one of the leading in-vitro diagnostic (IVD)
medical device companies in Korea,
backed by our commitment to exceptional quality.
Business Enhancement2020 - Present
We are evolving from an IVD-focused company into a global healthcare leader
Securing a foundation for growth2010 - 2019
We have expanded our business scope into immunoassay and molecular diagnostics.
Establishing a business foundation1996 - 2009
We laid the foundation for our biochemistry diagnostics business, with a focus on blood glucose monitoring system.
-
2025
• COVID-19/FLU combo self-test kit registered FDA 510(k) clearance (World's 1st)
-
2024
• Listed on KOSDAQ
• COVID-19/FLU combo self-test kit received FDA EUA (1st in Korea)
• Secured strategic investment in ALLEZ HEALTH and KRYPTOS BIOTECHNOLOGIES
• Received Growth Award on Korea Mid-Sized Enterprise
-
2023
• Signed strategic business partnership with Yuhan Corporation
-
2022
• Established Brazil subsidiary
• Selected as FIND LMICs supplier
• COVID-19 self-test kit received FDA EUA
-
2021
• Established U.S. subsidiary
-
2020
• COVID-19 PCR test kit received FDA EUA (1st in Korea)
-
2019
• Developed OTT-based digital healthcare platform
-
2017
• Renamed as OSANG HEALTHCARE Co., Ltd.
-
2016
• Acquired by the Osang Group
-
2013
• Entered molecular diagnostics business
-
2012
• Signed OEM agreement with HEMOCUE
-
2011
• Launched SelexON immunoassay device
-
2009
• Launched cholesterol analyzer
-
2008
• Launched HbA1c analyzer (1st in Korea)
-
2003
• Blood glucose meter approved by U.S. FDA (1st in Korea)
-
2001
• Developed blood glucose meter
-
1997
• Developed fully automated biochemistry analyzer (1st in Korea)
-
1996
• Established INFOPIA Co., Ltd.
2020 - Present
2010 - 2019
1996 - 2009
Business Enhancement
2020 - Present
We are evolving from an IVD-focused company into a global healthcare leader
-
2025
• COVID-19/FLU combo self-test kit registered FDA 510(k) clearance (World's 1st)
-
2024
• Listed on KOSDAQ • COVID-19/FLU combo self-test kit received FDA EUA (1st in Korea) • Secured strategic investment in ALLEZ HEALTH and KRYPTOS BIOTECHNOLOGIES • Received Growth Award on Korea Mid-Sized Enterprise
-
2023
• Signed strategic business partnership with Yuhan Corporation
-
2022
• Established Brazil subsidiary • Selected as FIND LMICs supplier • COVID-19 self-test kit received FDA EUA
-
2021
• Established U.S. subsidiary
-
2020
• COVID-19 PCR test kit received FDA EUA (1st in Korea)
Securing a foundation for growth
2010 - 2019
We have expanded our business scope into immunoassay and molecular diagnostics.
-
2019
• Developed OTT-based digital healthcare platform
-
2017
• Renamed as OSANG HEALTHCARE Co., Ltd.
-
2016
• Acquired by the Osang Group
-
2013
• Entered molecular diagnostics business
-
2012
• Signed OEM agreement with HEMOCUE
-
2011
• Launched SelexON immunoassay device
Establishing a business foundation
1996 - 2009
We laid the foundation for our biochemistry diagnostics business, with a focus on blood glucose monitoring system.
-
2009
• Launched cholesterol analyzer
-
2008
• Launched HbA1c analyzer (1st in Korea)
-
2003
• Blood glucose meter approved by U.S. FDA (1st in Korea)
-
2001
• Developed blood glucose meter
-
1997
• Developed fully automated biochemistry analyzer (1st in Korea)
-
1996
• Established INFOPIA Co., Ltd.